<DOC>
	<DOCNO>NCT02874287</DOCNO>
	<brief_summary>The purpose study evaluate whether treated hydroxychloroquine could improve therapeutic effect patient high-risk coronary artery disease .</brief_summary>
	<brief_title>Efficacy Study Hydroxychloroquine Treat High-risk Coronary Artery Disease .</brief_title>
	<detailed_description>This double blind , placebo , randomize control cross-over trial go assess hydroxychloroquine could improve high sensitivity C-reaction protein , blood lipid , blood glucose blood pressure , also whether hydroxychloroquine could affect secretion inflammatory cytokine M1/M2 phenotype polarization macrophages patient high-risk coronary artery disease .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Patients symptom angina STT change , well one coronary artery stenosis≥50 % least confirmed coronary angiography CT angiography age 1875 year old . High sensitivity Creactive protein &gt; 3mg/L , GRACE risk score≥90 . On guidelinebased secondary prevention coronary heart disease medications≥3 month . No use steroid , antibiotic , immunosuppressor week treatment . Retinal disease . Chronic hepatopathy . Renal dysfunction ( creatinine &gt; 175mmol/L ) . Moderately severe anemia , thrombocytopenia leukocytopenia . Other contraindication hydroxychloroquine . Active hemorrhage . Cancer life expectancy &lt; year . New York Heart Association ( NYHA ) functional class≥class III , Percutaneous Coronary Intervention Coronary Artery Bypass Grafting plan . Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Hydroxychloroquine</keyword>
	<keyword>Cross-Over Study</keyword>
</DOC>